Generic Name for Thiotepa
Thiotepa 15mg; per vial; lyophilized pwd for IV, intravesical, or intracavitary administration after reconstitution.
Legal Classification:
Rx
Pharmacological Class for Thiotepa
Alkylating agent.
Manufacturer of Thiotepa
Various generic manufacturers
|
Indications for Thiotepa
Adenocarcinomas of the ovary. Intracavitary effusion due to neoplasm of serosal cavities.
Other Indications for Thiotepa
Adult dose for Thiotepa
0.3–0.4mg/kg IV once every 1–4 weeks. Intracavitary administration: 0.6–0.8mg/kg through same tube used to remove fluid from cavity.
Children's dosing for Thiotepa
Not recommended.
Contraindications for Thiotepa
Renal, hepatic, or bone marrow dysfunction; if need outweighs risk, may be used in low dosage with close monitoring.
Warnings/Precautions for Thiotepa
Bone marrow suppression; monitor blood and platelets weekly during and for at least 3 weeks after therapy. Discontinue if WBC ≤3000/mm3 or platelets ≤150,000/mm3. Monitor renal and hepatic function. Use effective contraception if patient or partner is of childbearing potential. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Interactions for Thiotepa
Increased toxicity with concomitant or sequential alkylating agents (nitrogen mustards, cyclophosphamide), radiation, myelosuppressants. Prolonged apnea with succinylcholine.
Adverse Reactions for Thiotepa
Myelosuppression, fatigue, febrile or allergic reactions, inj site reactions, urinary retention, dysuria, GI disturbances, anorexia, alopecia, dizziness, headache, drowsiness, blurred vision, amenorrhea, interferes with spermatogenesis. Intravesical administration: rare: chemical or hemorrhagic cystitis.
How is Thiotepa supplied?
Contact supplier.